These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32803519)

  • 21. A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH.
    Zhu H; Chen X; Ahmed M; Wang Y; Liu Q; Uppoor RS; Kuemmel C; Mehta M
    Clin Transl Sci; 2019 Nov; 12(6):564-572. PubMed ID: 31169344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
    Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
    J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testing bioequivalence for multiple formulations with power and sample size calculations.
    Zheng C; Wang J; Zhao L
    Pharm Stat; 2012; 11(4):334-41. PubMed ID: 22692852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence: switchability and scaling.
    Midha KK; Rawson MJ; Hubbard JW
    Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets.
    Ibarra M; Magallanes L; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2016 Mar; 85():106-11. PubMed ID: 26850681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel scaled average bioequivalence limits based on GMR and variability considerations.
    Karalis V; Symillides M; Macheras P
    Pharm Res; 2004 Oct; 21(10):1933-42. PubMed ID: 15553242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bioequivalence assessment of pioglitazone hydrochloride oral preparation by limited sampling strategy].
    Ding JJ; Jiao Z; Li ZD; Shi XJ
    Yao Xue Xue Bao; 2006 Sep; 41(9):893-8. PubMed ID: 17111840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
    Cho HY; Yoon H; Park GK; Lee YB
    Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a limited sampling method used to determine the bioequivalence of highly variable drugs with long half-lives.
    Jackson AJ
    Biopharm Drug Dispos; 2001 Jul; 22(5):179-90. PubMed ID: 11745920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.
    Doki K; Darwich AS; Patel N; Rostami-Hodjegan A
    Eur J Pharm Sci; 2017 Nov; 109():111-120. PubMed ID: 28774813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons.
    Gwaza L; Gordon J; Potthast H; Welink J; Leufkens H; Stahl M; García-Arieta A
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1083-9. PubMed ID: 26105964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.